Drug Profile
Research programme: epicutaneous anti-infective vaccines - DBV Technologies/University of Geneva
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator DBV Technologies; University of Geneva
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Infections in France (Intradermal, Patch)
- 16 Jul 2016 No recent reports of development identified for research development in Infections in Switzerland (Intradermal, Patch)
- 11 Jun 2009 Early research in Infections in France (Intradermal)